Alector, Inc.
NASDAQ:ALECBiotechnology
+$0.08 today
- Market cap
- $382.61M
- Beta
- 0.59
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$1.13
Volume 2.13M
Average 0.65M
ALEC Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Alector, Inc.NASDAQ: ALEC
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue declines year over year
Q1 FY2026 revenue of $1.05M fell 71.5% year over year, ahead of the -79.2% change in trailing-twelve-month revenue. Sequentially, it fell 83.2% from the prior quarter. Over 3 fiscal years it compounded at -46.0% a year.
Context
- Revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 4 analysts of $186.46M (+786.0%) for the fiscal year ending Dec 2026, a step up from the -79.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $1.05M-83.2% QoQ
- Last fiscal yearDec 2025
- $21.05M-79.1% YoY
- LTMMar 2026
- $18.42M-79.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -71.5% | -78.2% | -6.7 pp |
| 1 year | -79.1% | +786.0% | +865.1 pp |
| 3-year CAGR | -46.0% | -24.7% | +21.3 pp |
| 5-year CAGR | -11.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 21.05M USD
- Year-over-year change
- -79.1%
- 4-year CAGR
- -43.5%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.05M | -79.1% |
| FY2024 | 2024-12-31 | 100.56M | +3.6% |
| FY2023 | 2023-12-31 | 97.06M | -27.4% |
| FY2022 | 2022-12-31 | 133.62M | -35.5% |
| FY2021 | 2021-12-31 | 207.09M | — |
Revenue vs competitors
How ALEC compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of -79.2% is the 3rd highest of 4, against a peer median of -52.6%.
- Over three fiscal years its annual growth of -46.0% compares with a peer median of -44.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $18.42M USD | -79.2% | -46.0% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $11.98M USD | -12.2% | -29.1% |
| LTM Mar 2026 | $6.32M USD | -52.6% | -59.0% | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | CHF 0 CHF | -100.0% | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| Peer median (excluding ALEC) | — | -52.6% | -44.0% | |
Competitors are the stored peer set for ALEC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 207.09M | 133.62M | 97.06M | 100.56M | 21.05M |
| Cost of Revenue | 189.41M | 0 | 8.85M | 185.94M | 9.66M |
| Gross Profit | 17.68M | 133.62M | 88.21M | (85.38M) | 11.38M |
| Gross Margin | 8.5% | 100.0% | 90.9% | -84.9% | 54.1% |
| Research & Development | 189.41M | 210.42M | 192.12M | 209.24M | 123.07M |
| Selling, General & Admin | 55.04M | 61.03M | 56.69M | 57.41M | 53.99M |
| Operating Expenses | 55.04M | 271.45M | 239.95M | 59.62M | 157.19M |
| Depreciation & Amortization | 8.32M | 8.47M | 8.85M | 8.84M | 9.66M |
| EBITDA | (28.01M) | (121.58M) | (116.33M) | (110.08M) | (133.1M) |
| EBITDA Margin | -13.5% | -91.0% | -119.9% | -109.5% | -632.5% |
| Operating Income | (37.36M) | (137.83M) | (151.74M) | (145M) | (145.81M) |
| Operating Margin | -18.0% | -103.2% | -156.3% | -144.2% | -692.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.03M | 7.78M | 26.56M | 26.08M | 3.05M |
| Income Before Tax | (36.33M) | (130.06M) | (125.18M) | (118.92M) | (142.76M) |
| Pre-Tax Margin | -17.5% | -97.3% | -129.0% | -118.3% | -678.4% |
| Income Tax Expense | 0 | 3.25M | 5.21M | 128K | 168K |
| Net Income | (36.33M) | (133.31M) | (130.39M) | (119.05M) | (142.93M) |
| Net Margin | -17.5% | -99.8% | -134.3% | -118.4% | -679.2% |
| EPS (Basic) | (0.45) | (1.62) | (1.56) | (1.23) | (1.39) |
| EPS (Diluted) | (0.45) | (1.62) | (1.56) | (1.23) | (1.39) |
| Weighted Avg Shares | 80.42M | 82.47M | 83.73M | 96.59M | 103M |
| Weighted Avg Shares (Diluted) | 80.42M | 82.47M | 83.73M | 96.59M | 103M |
Alector, Inc.
NASDAQ:ALEC
Intrinsic Alpha fair value
Locked
Current Price
$2.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.